Respuesta al tratamiento de la trombocitopenia inmune primaria en pediatría atendida en el servicio de hematología del Hospital del Niño Dr. Francisco de Icaza Bustamante, en el periodo 2018 al 2022.

Abstract

Primary immune thrombocytopenia (ITP) is a heterogeneous autoimmune condition with variability in etiology, bleeding phenotype, need for treatment and response to therapy, as well as disease duration. Fortunately, many children have mild bleeding and experience spontaneous resolution of the disease; however, it is not possible to predict which patients will have this outcome. OBJECTIVE: determine the response to treatment in children with primary immune thrombocytopenia at the Dr. Francisco de Icaza Bustamante Children's Hospital, during the period 2018 to 2022. METHODOLOGY: observational, descriptive, prospective and cross-sectional study. RESULTS: 133 patients were analyzed, 61.6% were boys, while 38.3% were girls, the average age was 5.7 years, the clinical manifestations they presented at the time of admission were; 122 (91.7%) petechiae, 111 (83.5%) ecchymoses, 45 (33.8) gingivorrhagia, 48 (36.1%) epistaxis, 12 (9%) hematuria, 16 (12%) hematemesis, 5 (3.8%) melena, the mean platelet value with which they were admitted was 13,585.71 mm3, the mean number of days they were hospitalized was 17.1 days, the patients who had the best response to treatment were children with 61.7% (p 0.01), the best response to treatment was with methylprednisone with 65.4% (p 0.01), followed by the use of immunoglobulin with 43.6% (p 0.01). ). CONCLUSIONS: the best response to the treatment of primary immune thrombocytopenia was observed with the administration of methylprednisolone followed by the use of intravenous immunoglobulin.